HDAC9 and malignant peripheral nerve sheath tumor: These include combination therapies involving MEK inhibitors,30 along with novel agents targeting HDAC, SHP2, TYK2, and CDK4/6 pathways.30, 31, 32 Furthermore, emerging evidence from these datasets highlights the therapeutic potential of immunomodulatory approaches in MPNST treatment.33